Immunopathogenesis of celiac disease

Current Gastroenterology Reports

Volumn 10, Issue 5, 2008, Pages 458-465

  Tye Din, Jason ^a   Anderson, Robert ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CCR9 BLOCKING AGENT; ENZYME INHIBITOR; GLIADIN; GLUTEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PEPTIDE VACCINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEINASE; RECEPTOR BLOCKING AGENT; TRANSGLUTAMINASE INHIBITOR; UNCLASSIFIED DRUG; ZONULIN INHIBITOR;

CD4+ T LYMPHOCYTE; CELIAC DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; DEAMINATION; DIETARY INTAKE; DIGESTION; ENVIRONMENTAL FACTOR; FOOD INTAKE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTESTINE BIOPSY; MOLECULAR MECHANICS; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; SMALL INTESTINE ABSORPTION; ARTICLE; GENETICS; IMMUNOLOGY;

CELIAC DISEASE; HUMANS;

EID: 58149352729     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0085-9     Document Type: Review

References (55)

1. Hausch F, Shan L, Santiago NA, et al.: Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002, 283: G996-G1003.
2. Shan L, Molberg O, Parrot I, et al.: Structural basis for gluten intolerance in celiac sprue. Science 2002, 297: 2275-2279.
3. Vader LW, Stepniak DT, Bunnik EM, et al.: Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 2003, 125: 1105-1113.
4. Vader W, Kooy Y, Van Veelen P, et al.: The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002, 122: 1729-1737.
5. Shan L, Qiao SW, Arentz-Hansen H, et al.: Identification and analysis of multivalent proteolytically resistant peptides from gluten: Implications for celiac sprue. J Proteome Res 2005, 4: 1732-1741.
6. Arentz-Hansen H, McAdam SN, Molberg O, et al.: Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 2002, 123: 803-809.
7. Arentz-Hansen H, Korner R, Molberg O, et al.: The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000, 191: 603-612.
8. Karell K, Louka AS, Moodie SJ, et al.: HLA types in celiac disease patients not carrying the DQA1*05-DQB1*Celiac Disease. Hum Immunol 2003, 64: 469-477.
9. Karinen H, Karkkainen P, Pihlajamaki J, et al.: Gene dose effect of the DQB1*0201 allele contributes to severity of coeliac disease. Scand J Gastroenterol 2006, 41: 191-199.
10. Vader W, Stepniak D, Kooy Y, et al.: The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci U S A 2003, 100: 12390-12395.
11. van Heel DA, Franke L, Hunt KA, et al.: A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007, 39: 827-829.
12. Hunt KA, Zhernakova A, Turner G, et al.: Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008, 40: 395-402.
13. Monsuur AJ, de Bakker PI, Alizadeh BZ, et al.: Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet 2005, 37: 1341-1344.
14. Hunt KA, Monsuur AJ, McArdle WL, et al.: Lack of association of MYO9B genetic variants with coeliac disease in a British cohort. Gut 2006, 55: 969-972.
15. Norris JM, Barriga K, Hoffenberg EJ, et al.: Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA 2005, 293: 2343-2351.
16. Ivarsson A, Persson LA, Hernell O: Does breast-feeding affect the risk for coeliac disease? Adv Exp Med Biol 2000, 478: 139-149.
17. Ivarsson A, Hernell O, Nystrom L, Persson LA: Children born in the summer have increased risk for coeliac disease. J Epidemiol Community Health 2003, 57: 36-39.
18. Stene LC, Honeyman MC, Hoffenberg EJ, et al.: Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: A longitudinal study. Am J Gastroenterol 2006, 101: 2333-2340.
19. Henderson KN, Tye-Din JA, Reid HH, et al.: A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Immunity 2007, 27: 23-34.
20. Schumann M, Richter JF, Wedell I, et al.: Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut 2008, 57: 747-754.
21. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, et al.: Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008, 205: 143-154.
22. Matysiak-Budnik T, Candalh C, Dugave C, et al.: Alterations of the intestinal transport and processing of gliadin peptides in celiac disease. Gastroenterology 2003, 125: 696-707.
23. Fasano A, Not T, Wang W, et al.: Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000, 355: 1518-1519.
24. Godkin AJ, Davenport MP, Willis A, et al.: Use of complete eluted peptide sequence data from HLA-DR and-DQ molecules to predict T cell epitopes, and the influence of the nonbinding terminal regions of ligands in epitope selection. J Immunol 1998, 161: 850-858.
25. Dieterich W, Ehnis T, Bauer M, et al.: Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997, 3: 797-801.
26. Molberg O, McAdam SN, Korner R, et al.: Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998, 4: 713-717. (Erratum appears in Nat Med 1998, 4:974.)
27. Fleckenstein B, Molberg O, Qiao SW, et al.: Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process. J Biol Chem 2002, 277: 34109-34116.
28. Vader LW, de Ru A, van der Wal Y, et al.: Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 2002, 195: 643-649.
29. Stepniak D, Koning F: Celiac disease - sandwiched between innate and adaptive immunity. Hum Immunol 2006, 67: 460-468.
30. Dieterich W, Esslinger B, Trapp D, et al.: Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease. Gut 2006, 55: 478-484.
31. van de Wal Y, Kooy Y, van Veelen P, et al.: Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998, 161: 1585-1588.
32. Kim CY, Quarsten H, Bergseng E, et al.: Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci U S A 2004, 101: 4175-4179.
33. Lundin KE, Scott H, Hansen T, et al.: Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993, 178: 187-196.
34. Molberg O, Kett K, Scott H, et al.: Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scand J Immunol 1997, 46(1): 103-108.
35. Lundin KE, Scott H, Fausa O, et al.: T cells from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient preferentially recognize gliadin when presented by DQ8. Hum Immunol 1994, 41: 285-291.
36. Nilsen EM, Lundin KE, Krajci P, et al.: Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 1995, 37: 766-776.
37. Ráki M, Fallang LE, Brottveit M, et al.: Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients. Proc Natl Acad Sci U S A 2007, 104: 2831-2836.
38. Qiao SW, Bergseng E, Molberg O, et al.: Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: Importance of proline spacing and glutamine deamidation. J Immunol 2005, 175: 254-261.
39. Arentz-Hansen H, Fleckenstein B, Molberg O, et al.: The molecular basis for oat intolerance in patients with celiac disease. PLoS Med 2004, 1: e1.
40. Anderson RP, Degano P, Godkin AJ, et al.: In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000, 6: 337-342.
41. van de Wal Y, Kooy YM, van Veelen PA, et al.: Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci U S A 1998, 95: 10050-10054.
42. Tollefsen S, Arentz-Hansen H, Fleckenstein B, et al.: HLA-DQ2 and-DQ8 signatures of gluten T cell epitopes in celiac disease. J Clin Invest 2006, 116: 2226-2236.
43. van de Wal Y, Kooy YM, van Veelen P, et al.: Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol 1999, 29: 3133-3139.
44. Gjertsen HA, Sollid LM, Ek J, et al.: T cells from the peripheral blood of coeliac disease patients recognize gluten antigens when presented by HLA-DR,-DQ, or-DP molecules. Scand J Immunol 1994, 39: 567-574.
45. Ben-Horin S, Green PH, Bank I, et al.: Characterizing the circulating, gliadin-specific CD4+ memory T cells in patients with celiac disease: linkage between memory function, gut homing and Th1 polarization. J Leukoc Biol 2006, 79: 676-685.
46. Anderson RP, van Heel DA, Tye-Din JA, et al.: T cells in peripheral blood after gluten challenge in coeliac disease. Gut 2005, 54: 1217-1223.
47. Beissbarth T, Tye-Din JA, Smyth GK, et al.: A systematic approach for comprehensive T-cell epitope discovery using peptide libraries. Bioinformatics 2005, 21(Suppl 1): I29-i37.
48. Gjertsen HA, Lundin KE, Sollid LM, et al.: T cells recognize a peptide derived from alpha-gliadin presented by the celiac disease-associated HLA-DQ (alpha 1*0501, beta 1*0201) heterodimer. Hum Immunol 1994, 39: 243-252.
49. Jabri B, de Serre NP, Cellier C, et al.: Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000, 118: 867-879.
50. Hue S, Mention JJ, Monteiro RC, et al.: A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004, 21: 367-377.
51. Meresse B, Chen Z, Ciszewski C, et al.: Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004, 21: 357-366.
52. Bhagat G, Naiyer AJ, Shah JG, et al.: Small intestinal CD8+ TCRγδ+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. J Clin Invest 2008, 118: 281-293.
53. Shepherd SJ, Gibson PR: Fructose malabsorption and symptoms of irritable bowel syndrome: Guidelines for effective dietary management. J Am Diet Assoc 2006, 106: 1631-1639.
54. Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD: Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology 2001, 121: 1329-1338.
55. Kunkel EJ, Campbell JJ, Haraldsen G, et al.: Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000, 192: 761-768.